DPP-IV Inhibitors

Global Market Trajectory & Analytics

MCP-6466

EXECUTIVE ENGAGEMENTS

POOL

4609
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

832
Interactions with Platform & by Email

PARTICIPANTS

138
Unique # Participated

VALIDATIONS

42
Responses Validated*

COMPANIES

14
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

18

PAGES

62

EDITION

16

PRICE

USD 5450

CODE

MCP-6466


COMPETITIVE METRICS

COMPANY

WORLD RANK & SHARE

D S N T

% *

AstraZeneca PLC

Login Required

Boehringer Ingelheim International GmbH

Login Required

Daiichi Sankyo Co., Ltd.

Login Required

Dong-A ST Co., Ltd.

Login Required

Dr. Reddy`s Laboratories Ltd.

Login Required

Eli Lilly and Company

Login Required

Glenmark Pharmaceuticals Ltd.

Login Required

Kowa Co., Ltd.

Login Required

Kyowa Kirin Co., Ltd.

Login Required

Lupin Ltd.

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 14 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for DPP-IV Inhibitors estimated at US$8.9 Billion in the year 2020, is projected to reach a revised size of US$10.4 Billion by 2027, growing at a CAGR of 2.3% over the period 2020-2027.
The DPP-IV Inhibitors market in the U.S. is estimated at US$2.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 2.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 1.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

SELECT PLAYERS

AstraZeneca Plc.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck & Co. Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis AG; Takeda Pharmaceutical Company Limited

SEGMENTS

» Segment (DPP-IV Inhibitors)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks
Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
Recent Market Activity
TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
Management of T2DM with DPP-4 Combination Therapy
FDA Approves Merck’s First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Eli Lilly and Company (USA)
Merck & Co, Inc. (USA)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
CANADA
Canada Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
JAPAN
Japan Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
CHINA
China Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
EUROPE
Europe Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
FRANCE
France Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
GERMANY
Germany Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
ITALY
Italy Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Total Companies Profiled: 14

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com